February 2024

Approval is based on the Phase 3 KEYNOTE-811 Trial KIRKLAND, QC, Feb. 12, 2024 /CNW/ – Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced that Health Canada has granted approval of  KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: